<DOC>
	<DOC>NCT02933866</DOC>
	<brief_summary>A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS topical product in Patients with Mild to Severe Scalp Psoriasis</brief_summary>
	<brief_title>Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis</brief_title>
	<detailed_description>To evaluate the therapeutic efficacy and safety of DSXS topical product (Taro Pharmaceuticals, U.S.A., Inc.) compared to a Vehicle topical product (Taro Pharmaceuticals, U.S.A., Inc.) in patients with mild to severe scalp psoriasis.</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male or nonpregnant, nonlactating females 18 years of age and older. Females who are pregnant, lactating or likely to become pregnant during the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>